During the past decade, Eulji General Hospital conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 6 clinical trials were completed, i.e. on average, 17.1% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 4 clinical trials were completed. i.e. 26.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Eulji General Hospital" #1 sponsor was "H. Lundbeck A/S" with 3 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Seung-Jung Park" with 3 trials sponsored, "Sewon Cellontech Co., Ltd." with 3 trials sponsored and "ATGC Co., Ltd." with 3 trials sponsored. Other sponsors include 34 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Eulji General Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 4 trials as a collaborator, "Astellas Pharma Korea, Inc." with 1 trials as a collaborator, "Baxter Healthcare Corporation" with 1 trials as a collaborator, "BioShin Limited" with 1 trials as a collaborator and "Boston Scientific Korea Co. Ltd" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Eulji General Hospital" are "Coronary Artery Disease" (3 trials), "Glabellar Frown Lines" (3 trials), "Hypertension" (3 trials), "Migraine" (3 trials) and "Benign Prostatic Hyperplasia (BPH)" (2 trials). Many other conditions were trialed in "Eulji General Hospital" in a lesser frequency.

Most popular intervention types in "Eulji General Hospital" are "Drug" (30 trials), "Device" (8 trials), "Biological" (7 trials), "Other" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "ALLO-ASC-DFU" (2 trials), "Botox®" (2 trials), "Eptinezumab" (2 trials) and "ATGC-100" (1 trials). Other intervention names were less common.

The vast majority of trials in "Eulji General Hospital" are 49 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Eulji General Hospital". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 31 completed trials in Eulji General Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Eulji General Hospital, 3 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 2 trials that are defined as “Not Applicable".